Literature DB >> 23378033

Inclusions in frontotemporal lobar degeneration with TDP-43 proteinopathy (FTLD-TDP) and amyotrophic lateral sclerosis (ALS), but not FTLD with FUS proteinopathy (FTLD-FUS), have properties of amyloid.

Eileen H Bigio, Jane Y Wu, Han-Xiang Deng, Esther N Bit-Ivan, Qinwen Mao, Rakhee Ganti, Melanie Peterson, Nailah Siddique, Changiz Geula, Teepu Siddique, Marsel Mesulam.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23378033      PMCID： PMC3593646          DOI： 10.1007/s00401-013-1089-6

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN： 0001-6322            Impact factor:   17.088


× No keyword cloud information.
  8 in total

1.  Staining methods for identification of amyloid in tissue.

Authors:  G T Westermark; K H Johnson; P Westermark
Journal:  Methods Enzymol       Date:  1999       Impact factor: 1.600

Review 2.  Gains or losses: molecular mechanisms of TDP43-mediated neurodegeneration.

Authors:  Edward B Lee; Virginia M-Y Lee; John Q Trojanowski
Journal:  Nat Rev Neurosci       Date:  2011-11-30       Impact factor: 34.870

3.  An ALS-associated mutation affecting TDP-43 enhances protein aggregation, fibril formation and neurotoxicity.

Authors:  Weirui Guo; Yanbo Chen; Xiaohong Zhou; Amar Kar; Payal Ray; Xiaoping Chen; Elizabeth J Rao; Mengxue Yang; Haihong Ye; Li Zhu; Jianghong Liu; Meng Xu; Yanlian Yang; Chen Wang; David Zhang; Eileen H Bigio; Marsel Mesulam; Yan Shen; Qi Xu; Kazuo Fushimi; Jane Y Wu
Journal:  Nat Struct Mol Biol       Date:  2011-06-12       Impact factor: 15.369

Review 4.  TDP-43 functions and pathogenic mechanisms implicated in TDP-43 proteinopathies.

Authors:  Todd J Cohen; Virginia M Y Lee; John Q Trojanowski
Journal:  Trends Mol Med       Date:  2011-07-23       Impact factor: 11.951

5.  Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B.

Authors:  William E Klunk; Henry Engler; Agneta Nordberg; Yanming Wang; Gunnar Blomqvist; Daniel P Holt; Mats Bergström; Irina Savitcheva; Guo-feng Huang; Sergio Estrada; Birgitta Ausén; Manik L Debnath; Julien Barletta; Julie C Price; Johan Sandell; Brian J Lopresti; Anders Wall; Pernilla Koivisto; Gunnar Antoni; Chester A Mathis; Bengt Långström
Journal:  Ann Neurol       Date:  2004-03       Impact factor: 10.422

6.  TDP-43 skeins show properties of amyloid in a subset of ALS cases.

Authors:  John L Robinson; Felix Geser; Anna Stieber; Mfon Umoh; Linda K Kwong; Vivianna M Van Deerlin; Virginia M-Y Lee; John Q Trojanowski
Journal:  Acta Neuropathol       Date:  2012-11-03       Impact factor: 17.088

7.  In vivo amyloid imaging with PET in frontotemporal dementia.

Authors:  Henry Engler; Alexander Frizell Santillo; Shu Xia Wang; Maria Lindau; Irina Savitcheva; Agneta Nordberg; Lars Lannfelt; Bengt Långström; Lena Kilander
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-09-11       Impact factor: 9.236

Review 8.  Regulated protein aggregation: stress granules and neurodegeneration.

Authors:  Benjamin Wolozin
Journal:  Mol Neurodegener       Date:  2012-11-20       Impact factor: 14.195
  8 in total
  44 in total

1.  The role of liquid-liquid phase separation in aggregation of the TDP-43 low-complexity domain.

Authors:  W Michael Babinchak; Raza Haider; Benjamin K Dumm; Prottusha Sarkar; Krystyna Surewicz; Jin-Kyu Choi; Witold K Surewicz
Journal:  J Biol Chem       Date:  2019-02-27       Impact factor: 5.157

Review 2.  TDP-43 Prions.

Authors:  Takashi Nonaka; Masato Hasegawa
Journal:  Cold Spring Harb Perspect Med       Date:  2018-03-01       Impact factor: 6.915

Review 3.  Liquid-Liquid Phase Separation and Its Mechanistic Role in Pathological Protein Aggregation.

Authors:  W Michael Babinchak; Witold K Surewicz
Journal:  J Mol Biol       Date:  2020-03-10       Impact factor: 5.469

Review 4.  Application of yeast to studying amyloid and prion diseases.

Authors:  Yury O Chernoff; Anastasia V Grizel; Aleksandr A Rubel; Andrew A Zelinsky; Pavithra Chandramowlishwaran; Tatiana A Chernova
Journal:  Adv Genet       Date:  2020-05-04       Impact factor: 1.944

5.  An ALS-mutant TDP-43 neurotoxic peptide adopts an anti-parallel β-structure and induces TDP-43 redistribution.

Authors:  Li Zhu; Meng Xu; Mengxue Yang; Yanlian Yang; Yang Li; Jianwen Deng; Linhao Ruan; Jianghong Liu; Sidan Du; Xuehui Liu; Wei Feng; Kazuo Fushimi; Eileen H Bigio; Marsel Mesulam; Chen Wang; Jane Y Wu
Journal:  Hum Mol Genet       Date:  2014-08-11       Impact factor: 6.150

6.  Subcellular localization and RNAs determine FUS architecture in different cellular compartments.

Authors:  Liuqing Yang; Jiayu Zhang; Marisa Kamelgarn; Chunyan Niu; Jozsef Gal; Weimin Gong; Haining Zhu
Journal:  Hum Mol Genet       Date:  2015-06-29       Impact factor: 6.150

7.  Morphology and Distribution of TDP-43 Pre-inclusions in Primary Progressive Aphasia.

Authors:  Garam Kim; Kabriya Bolbolan; Ryan Shahidehpour; Pouya Jamshidi; Tamar Gefen; Ivan A Ayala; Sandra Weintraub; Eileen H Bigio; Marek-Marsel Mesulam; Changiz Geula
Journal:  J Neuropathol Exp Neurol       Date:  2019-03-01       Impact factor: 3.685

8.  Detection of TAR DNA-binding protein 43 (TDP-43) oligomers as initial intermediate species during aggregate formation.

Authors:  Rachel L French; Zachary R Grese; Himani Aligireddy; Dhruva D Dhavale; Ashley N Reeb; Niraja Kedia; Paul T Kotzbauer; Jan Bieschke; Yuna M Ayala
Journal:  J Biol Chem       Date:  2019-03-01       Impact factor: 5.157

9.  Intranuclear aggregation of mutant FUS/TLS as a molecular pathomechanism of amyotrophic lateral sclerosis.

Authors:  Takao Nomura; Shoji Watanabe; Kumi Kaneko; Koji Yamanaka; Nobuyuki Nukina; Yoshiaki Furukawa
Journal:  J Biol Chem       Date:  2013-11-26       Impact factor: 5.157

10.  Structural Evidence of Amyloid Fibril Formation in the Putative Aggregation Domain of TDP-43.

Authors:  Miguel Mompeán; Rubén Hervás; Yunyao Xu; Timothy H Tran; Corrado Guarnaccia; Emanuele Buratti; Francisco Baralle; Liang Tong; Mariano Carrión-Vázquez; Ann E McDermott; Douglas V Laurents
Journal:  J Phys Chem Lett       Date:  2015-06-22       Impact factor: 6.475
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.